Inaugural Cohort · 2026

Psio

Precision neurofeedback for ketamine and psychedelic-assisted therapy.

Devin Effinger, PhD · devin@psio.app

Two limits on psychedelic therapy

Psychedelic therapy works.
The brain-state window closes too fast.

A ketamine or psilocybin session opens a powerful window of heightened neuroplasticity — but the window is brief, outcomes vary wildly, and the clinician is flying blind. Most of the therapeutic potential goes untapped.

01 Limit

Limited plasticity window

The neuroplastic opening closes before integration consolidates, leaving most of the therapeutic potential locked behind a single session.

02 Limit

Highly variable outcomes

Response varies widely across individuals — shaped by neurobiology, set, setting, and integration. Clinics can't predict, measure, or reinforce what's working.

Starting point → core action → result

Let's run the loop.

Three surfaces, one signal. Everything you're about to see is the real product running on real EEG.

01 Starting point

A session begins

The facilitator sees the client's brain state, live.

02 Core action

The breakthrough is captured

The peak of the session becomes data the clinic can act on.

03 Result

It goes home with the client

The work continues between sessions instead of fading.

Starting point · Facilitator Portal

A session begins — the brain comes online.

The client puts on a wearable EEG headset. One click and the facilitator is watching their brain state live.

Live EEG — brain activity streaming in real time from a comfortable wearable.
Personalized from the start — everything is anchored to this client's own brain, not a population average.
Purpose-built session audio — an immersive soundscape designed for the therapeutic setting.

Live · Facilitator Portal α 11.3 Hz

Core action · Breakthrough capture

The breakthrough happens — and we capture it.

This is the moment that proves the value: the peak of the session becomes measurable insight instead of just a memory.

In-session capture — key moments are captured as they happen, without disrupting the session.
Proprietary analysis — Psio's algorithms identify what changed in the client's brain function.
Clinic-wide view — every client and session lands in the dashboard, ready to guide what happens next.

psio.app / dashboard v0.9

Result · Client App

The healing goes home — the window stays open.

The outcome the client walks away with: their breakthrough, reinforced daily between sessions instead of fading.

Daily neurofeedback — a few minutes a day, personalized to each client.
Continuity between sessions — familiar elements of the session experience carry into home practice.
Longitudinal scores — client and clinic both watch progress across the full arc of care.

Versus the alternatives — including doing nothing

The only closed loop
in psychedelic care.

Psio isn't a general neurofeedback tool pointed at psychedelics. It's neural infrastructure purpose-built for ketamine and psychedelic-assisted therapy.

01 Category

Purpose-built for PAT / KAT

Every part of the workflow is modeled on how psychedelic care actually runs — not retrofitted from legacy neurofeedback.

02 Loop

Alternatives don't close the loop

Doing nothing means subjective self-report. Session-capture tools and EHRs record what was said. None of them measure the brain — and none reinforce what worked.

03 Data

Every session compounds

Each session grows the first longitudinal brain-state dataset in psychedelic care — across both psilocybin and ketamine tracks. First to the data is first to the category.

At this stage, the metric that matters is data

Real sessions. Real signal.
First revenue.

Usage Live

5

psilocybin sessions run on the platform

Real clients, real EEG, the full loop — from live session capture through post-session analysis.

Signal Detected

The algorithm is finding the signal

Across those sessions, our algorithm has detected changes in brain function associated with positive change and breakthrough moments — the core technical bet, working on real-world data.

Revenue Paying

1

paying neurofeedback customer

First revenue on the platform — proof that the neurofeedback layer stands on its own.

Pipeline Committed

3

pilot sites committed

Three sites committed to piloting Psio — spanning both the ketamine and psilocybin tracks. Every site multiplies the dataset.

The next two quarters

From five sessions
to a dataset.

01 Deploy

Run the pilots

Stand up all three committed pilot sites and take session volume from five to dozens — hardening the platform in real clinical settings.

02 Automate

Automate session analysis

Every session's EEG automatically becomes a clinician-ready analysis and narrative report — so insight scales with volume, not headcount.

03 Evidence

Grow the evidence

Build the normative and longitudinal dataset, pursue NIH SBIR-backed biomarker research, and turn pilot data into seed-ready proof.

First to the data is first to the category.

Questions?

Psio · neural infrastructure for psychedelic care.